141 related articles for article (PubMed ID: 9987567)
1. The influence of tamoxifen on the maturation index of vaginal epithelium.
Friedrich M; Mink D; Villena-Heinsen C; Woll-Hermann A; Wagner S; Schmidt W
Clin Exp Obstet Gynecol; 1998; 25(4):121-4. PubMed ID: 9987567
[TBL] [Abstract][Full Text] [Related]
2. Tamoxifen and proliferation of vaginal and cervical epithelium in postmenopausal women with breast cancer.
Friedrich M; Mink D; Villena-Heinsen C; Woll-Hermann A; Schmidt W
Eur J Obstet Gynecol Reprod Biol; 1998 Oct; 80(2):221-5. PubMed ID: 9846673
[TBL] [Abstract][Full Text] [Related]
3. Ultrasonography of the endometrium and endometrial pathology under tamoxifen treatment.
Friedrich M; Villena-Heinsen C; Mink D; Endres V; Reitnauer K; Schmidt W
Eur J Gynaecol Oncol; 1998; 19(6):536-40. PubMed ID: 10215436
[TBL] [Abstract][Full Text] [Related]
4. The effects of tamoxifen on the vaginal epithelium in postmenopausal women.
Love RR; Kurtycz DF; Dumesic DA; Laube DW; Yang Y
J Womens Health Gend Based Med; 2000 Jun; 9(5):559-63. PubMed ID: 10883948
[TBL] [Abstract][Full Text] [Related]
5. Maturation of vaginal and endometrial epithelium in postmenopausal breast cancer patients receiving long-term tamoxifen.
Lahti E; Vuopala S; Kauppila A; Blanco G; Ruokonen A; Laatikainen T
Gynecol Oncol; 1994 Dec; 55(3 Pt 1):410-4. PubMed ID: 7835781
[TBL] [Abstract][Full Text] [Related]
6. Effect of tamoxifen on GH and IGF-1 serum level in stage I-II breast cancer patients.
Mandalà M; Moro C; Ferretti G; Calabro MG; Nolè F; Rocca A; Munzone E; Castro A; Curigliano G
Anticancer Res; 2001; 21(1B):585-8. PubMed ID: 11299809
[TBL] [Abstract][Full Text] [Related]
7. Comparison between the effects of tamoxifen and toremifene on the uterus in postmenopausal breast cancer patients.
Tomás E; Kauppila A; Blanco G; Apaja-Sarkkinen M; Laatikainen T
Gynecol Oncol; 1995 Nov; 59(2):261-6. PubMed ID: 7590484
[TBL] [Abstract][Full Text] [Related]
8. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
Coates AS; Keshaviah A; Thürlimann B; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Colleoni M; Láng I; Del Mastro L; Smith I; Chirgwin J; Nogaret JM; Pienkowski T; Wardley A; Jakobsen EH; Price KN; Goldhirsch A
J Clin Oncol; 2007 Feb; 25(5):486-92. PubMed ID: 17200148
[TBL] [Abstract][Full Text] [Related]
9. Estrogenic effects of toremifene and tamoxifen in postmenopausal breast cancer patients.
Ellmén J; Hakulinen P; Partanen A; Hayes DF
Breast Cancer Res Treat; 2003 Nov; 82(2):103-11. PubMed ID: 14692654
[TBL] [Abstract][Full Text] [Related]
10. [Letrozole vs. tamoxifen as neoadjuvant therapy for postmenopausal patients with hormone-dependent locally-advanced breast cancer].
Novoa Vargas A; Font López KC; Amador DD
Ginecol Obstet Mex; 2011 Sep; 79(9):553-7. PubMed ID: 21966856
[TBL] [Abstract][Full Text] [Related]
11. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer.
Coombes RC; Hall E; Gibson LJ; Paridaens R; Jassem J; Delozier T; Jones SE; Alvarez I; Bertelli G; Ortmann O; Coates AS; Bajetta E; Dodwell D; Coleman RE; Fallowfield LJ; Mickiewicz E; Andersen J; Lønning PE; Cocconi G; Stewart A; Stuart N; Snowdon CF; Carpentieri M; Massimini G; Bliss JM; van de Velde C;
N Engl J Med; 2004 Mar; 350(11):1081-92. PubMed ID: 15014181
[TBL] [Abstract][Full Text] [Related]
12. The nature of tamoxifen action in the control of female breast cancer.
Kodama M; Kodama T
In Vivo; 2001; 15(4):319-25. PubMed ID: 11695224
[TBL] [Abstract][Full Text] [Related]
13. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.
; Thürlimann B; Keshaviah A; Coates AS; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Rabaglio M; Smith I; Wardley A; Price KN; Goldhirsch A
N Engl J Med; 2005 Dec; 353(26):2747-57. PubMed ID: 16382061
[TBL] [Abstract][Full Text] [Related]
14. Prospective study on gynaecological effects of two antioestrogens tamoxifen and toremifene in postmenopausal women.
Marttunen MB; Cacciatore B; Hietanen P; Pyrhönen S; Tiitinen A; Wahlström T; Ylikorkala O
Br J Cancer; 2001 Apr; 84(7):897-902. PubMed ID: 11286468
[TBL] [Abstract][Full Text] [Related]
15. Effect of adjuvant tamoxifen therapy on thyroid function in postmenopausal women with breast cancer.
Zidan J; Rubenstein W
Oncology; 1999; 56(1):43-5. PubMed ID: 9885376
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of tamoxifen resistance in the treatment of advanced breast cancer.
Lykkesfeldt AE
Acta Oncol; 1996; 35 Suppl 5():9-14. PubMed ID: 9142958
[TBL] [Abstract][Full Text] [Related]
17. Comparison of endometrial changes among symptomatic tamoxifen-treated and nontreated premenopausal and postmenopausal breast cancer patients.
Cheng WF; Lin HH; Torng PL; Huang SC
Gynecol Oncol; 1997 Aug; 66(2):233-7. PubMed ID: 9264568
[TBL] [Abstract][Full Text] [Related]
18. Pharmacoeconomic analysis of adjuvant therapy with exemestane, anastrozole, letrozole or tamoxifen in postmenopausal women with operable and estrogen receptor-positive breast cancer.
Gil JM; Rubio-Terrés C; Del Castillo A; González P; Canorea F
Clin Transl Oncol; 2006 May; 8(5):339-48. PubMed ID: 16760009
[TBL] [Abstract][Full Text] [Related]
19. Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer.
Newby JC; Johnston SR; Smith IE; Dowsett M
Clin Cancer Res; 1997 Sep; 3(9):1643-51. PubMed ID: 9815855
[TBL] [Abstract][Full Text] [Related]
20. The effect of tamoxifen on PCNA expression in fibroadenomas.
Bernardes JR; Seixas MT; Lima GR; Marinho LC; Gebrim LH
Breast J; 2003; 9(4):302-6. PubMed ID: 12846865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
